title: Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
abstract: Turoctocog alfa (NovoEight®) is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid 720, and a monoclonal antibody binding C-terminal to this position is used in the purification process allowing isolation of the intact rFVIII. Viral inactivation is ensured by a detergent inactivation step as well as a 20-nm nano-filtration step. Characterisation of the purified protein demonstrated that turoctocog alfa was fully sulphated at Tyr346 and Tyr1664, which is required for optimal proteolytic activation by thrombin. Kinetic assessments confirmed that turoctocog alfa was activated by thrombin at a similar rate as seen for other rFVIII products fully sulphated at these positions. Tyr1680 was also fully sulphated in turoctocog alfa resulting in strong affinity (low nm Kd ) for binding to von Willebrand factor (VWF). Half-lives of 7.2 ± 0.9 h in F8-KO mice and 8.9 ± 1.8 h haemophilia A dogs supported that turoctocog alfa bound to VWF after infusion. Functional studies including thromboelastography analysis of human haemophilia A whole blood with added turoctocog alfa and effect studies in mice bleeding models demonstrated a dose-dependent effect of turoctocog alfa. The non-clinical data thus confirm the haemostatic effect of turoctocog alfa and, together with the comprehensive clinical evaluation, support the use as FVIII replacement therapy in patients with haemophilia A.
authors.affiliation: Novo Nordisk A/S, Maaloev, Denmark.
authors.forename: Mirella
authors.initials: M
authors.lastname: Ezban
authors.forename: Knud
authors.initials: K
authors.lastname: Vad
authors.forename: Marianne
authors.initials: M
authors.lastname: Kjalke
mesh_terms: D000818:Animals; D016466:CHO Cells; D003412:Cricetulus; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005169:Factor VIII / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification / Q000493:pharmacokinetics*; D015870:Gene Expression; D006031:Glycosylation; D006207:Half-Life; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D007700:Kinetics; D051379:Mice; D046188:Protein Modification, Translational; D011499:Protein Processing, Post-Translational; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification / Q000493:pharmacokinetics; D013431:Sulfates; D013917:Thrombin / Q000378:metabolism
chemical_list: D011994:Recombinant Proteins; D013431:Sulfates; C577506:recombinant factor VIII N8; D005169:Factor VIII; D013917:Thrombin
keywords: N8; haemophilia A; rFVIII; recombinant factor VIII; turoctocog alfa